Stock listing
Racura Oncology Ltd
Selected listing: FN3 · GETTEX · EUR · DE
Racura Oncology Ltd (gettex:FN3), Health Technology. Latest release Aug 31, 2026: CPACS Trial Opens for RC220 Patient Enrolment in Korea.
- Ticker
- gettex:FN3
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- gettex
- Currency
- EUR
About Racura Oncology Ltd
The company focuses on developing innovative therapies for cancer treatment. Racura Oncology aims to advance its research and development efforts to improve patient outcomes in oncology.
Latest news from Racura Oncology Ltd
CPACS Trial Opens for RC220 Patient Enrolment in Korea
August 31, 2026
First HARNESS-1 Patient Safely Treated with RC220
July 28, 2026
June 2026 Quarterly Activities Report and Appendix 4C
July 27, 2026
Bellberry Ethics Approval Activates New HARNESS Trial Sites
July 2, 2026
Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 in EGFR-Mutant Non-Small Cell Lung Cancer
June 25, 2026
Research Racura Oncology Ltd
Alternate listings
RAC:ASX
AU · AUD
Alternate listing for Racura Oncology Ltd; the primary context on this page is FN3:GETTEX.
FN3:FWB
DE · EUR
Alternate listing for Racura Oncology Ltd; the primary context on this page is FN3:GETTEX.
FN3:MUN
DE · EUR
Alternate listing for Racura Oncology Ltd; the primary context on this page is FN3:GETTEX.